Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind trial of YB211 (kynomycin) vs daptomycin for acute bacterial skin and skin structure infections
CTR20250665Phase 2Active
- Sponsor
- Mudanjiang Youbo Pharmaceutical
- Start
- May 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of kynomycin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Mudanjiang Youbo Pharmaceutical. Started May 2025; status: active.
02
Drugs
kynomycin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on CTR20250665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250665.